Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465752 | 0.93 | PARP1 (0.37) | HSD17B10PARP1PPARGRAB9ANCOA3 | |
| SCHEMBL5472790 | 0.93 | PARP1 (0.36) | HSD17B10PARP1 | |
| SCHEMBL5467227 | 0.86 | PARP1 (0.32) | HSD17B10PARP1 | |
| SCHEMBL5472751 | 0.86 | PARP1 (0.33) | PARP1 | |
| SCHEMBL5474592 | 0.85 | PARP1 (0.45) | HSD17B10PARP1PPARGRAB9ANCOA3 | |
| SCHEMBL5473218 | 0.83 | PPARG (0.30) | PPARGRAB9ANCOA3 | |
| SCHEMBL5465466 | 0.81 | PARP1 (0.44) | HSD17B10PARP1TP53POLBSMN1; SMN2 | |
| SCHEMBL5464877 | 0.79 | PARP1 (0.32) | PARP1 | |
| SCHEMBL5854159 | 0.78 | PARP1 (0.32) | PARP1 | |
| SCHEMBL5464744 | 0.77 | PARP1 (0.47) | HSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-7141566-B1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | CYP3A5, XDH, CYP4Z1 | HSD17B10 1504/4885PARP1 2890/4885PPARG 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.